|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Efficacy and Safety of Topical KX-826 Solution in Chinese Male Patients With Androgenetic Alopecia: A Multicenter, Randomized, Double-blind, Vehicle Controlled Adaptive Design Phase 2/3 Study
This study is a multicenter, randomized, double-blind, vehicle controlled, adaptive design phase 2/3 study to evaluate the efficacy and safety of topical KX-826 solution in Chinese male patients with androgenetic alopecia (AGA). It consisted of two phases, phase 2 dose exploration trial and phase 3 confirmatory trial.
评价KX-826酊1.0%在中国成年雄激素性秃发受试者中局部外用多次给药的安全耐受性,药代动力学特征的I期临床试验
[Translation] A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of Topical Multiple-Dosage KX-826 Tincture 1.0% in Chinese Adult Subjects with Androgenetic Alopecia
评价KX-826酊1.0%在中国成年雄激素性秃发受试者中局部外用多次给药的安全性、耐受性和药代动力学特征。
[Translation] To evaluate the safety, tolerability, and pharmacokinetic profile of topical multiple-dose KX-826 tincture 1.0% in Chinese adult subjects with androgenetic alopecia.
评价KX-826凝胶1.0%在中国成年寻常痤疮受试者中局部外用多次给药的安全耐受性、药代动力学特征的I期临床试验
[Translation] A Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of KX-826 gel 1.0% in Chinese adult subjects with acne vulgaris after multiple topical administration
评价KX-826凝胶1.0%在中国成年寻常痤疮受试者中局部外用多次给药的安全性、耐受性和药代动力学特征
[Translation] To evaluate the safety, tolerability, and pharmacokinetic characteristics of KX-826 gel 1.0% after multiple topical administration in Chinese adult subjects with acne vulgaris
100 Clinical Results associated with Suzhou Pioneer Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Suzhou Pioneer Pharmaceutical Co., Ltd.
100 Deals associated with Suzhou Pioneer Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Suzhou Pioneer Pharmaceutical Co., Ltd.